[關(guān)鍵詞]
[摘要]
胰高血糖素樣肽-1受體激動(dòng)劑(GLP-1RAs)治療2型糖尿病受到廣泛關(guān)注,其不僅具有優(yōu)異的降糖優(yōu)勢,還有控制體質(zhì)量,調(diào)節(jié)血脂,改善胰島β細(xì)胞功能等特點(diǎn),同時(shí)低血糖或體質(zhì)量增加的不良反應(yīng)發(fā)生率較低。自2005年至今,已經(jīng)有7個(gè)GLP-1RAs經(jīng)美國食品藥品監(jiān)督管理局批準(zhǔn)上市,即艾塞那肽、利拉魯肽、艾塞那肽長效制劑、阿必魯肽、度拉糖肽、利西拉來和索馬魯肽;在中國上市的有貝那魯肽和洛塞那肽。對已經(jīng)上市的9個(gè)GLP-1Ras治療2型糖尿病的臨床研究進(jìn)展進(jìn)行綜述。
[Key word]
[Abstract]
Glucagon-like peptide-1 receptor agonists(GLP-1RAs)are widely used in the treatment of type 2 diabetes mellitus. GLP- 1RAs not only has the advantages of reducing blood glucose, but also has the characteristics of controlling body mass, regulating blood lipid, improving the function of islet beta cells.At the same time, the incidence of adverse reactions caused by hypoglycemia or increased body mass is relatively low. Since 2005, seven GLP-1RAs have been approved by the U. S. Food and Drug Administration for listing, i. e. exenatide, liraglutide, exenatide long-acting preparation, albiglutide, dulaglutide, lixisenatide and semaglutide; beinaglutide and loxenatide are listed in China. The clinical research progress of nine GLP-1RAs in the treatment of type 2 diabetes was reviewed.
[中圖分類號(hào)]
R944.5
[基金項(xiàng)目]
天津市科技計(jì)劃項(xiàng)目(19YFZCSY00630,19YFZCSY00630)